303 related articles for article (PubMed ID: 30795697)
21. The pharmacokinetics of therapeutic arsenic trioxide in acute promyelocytic leukemia patients.
Ghiuzeli CM; Stýblo M; Saunders J; Calabro A; Budman D; Allen S; Devoe C; Dhingra R
Leuk Lymphoma; 2022 Mar; 63(3):653-663. PubMed ID: 34689693
[TBL] [Abstract][Full Text] [Related]
22. Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3.
Šlejkovec Z; Podgornik H; Černelč P; Falnoga I
Biometals; 2016 Feb; 29(1):107-18. PubMed ID: 26671504
[TBL] [Abstract][Full Text] [Related]
23. HPLC-HG-AFS determination of arsenic species in acute promyelocytic leukemia (APL) plasma and blood cells.
Guo M; Wang W; Hai X; Zhou J
J Pharm Biomed Anal; 2017 Oct; 145():356-363. PubMed ID: 28711674
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As
Liu WS; Wang XY; Lu J; Zhang YM; Ye XM; Li JM; Zhao QL; Wu ZQ; Zhou J; Hai X
Arch Toxicol; 2020 Apr; 94(4):1203-1213. PubMed ID: 32112223
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic Properties of Arsenic Species after Intravenous and Intragastrical Administration of Arsenic Trioxide Solution in Cynomolgus Macaques Using HPLC-ICP-MS.
Shi Q; Ju M; Zhu X; Gan H; Gu R; Wu Z; Meng Z; Dou G
Molecules; 2019 Jan; 24(2):. PubMed ID: 30634677
[TBL] [Abstract][Full Text] [Related]
26. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Wang QQ; Hua HY; Naranmandura H; Zhu HH
Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
[TBL] [Abstract][Full Text] [Related]
27. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia.
Yoshino Y; Yuan B; Miyashita SI; Iriyama N; Horikoshi A; Shikino O; Toyoda H; Kaise T
Anal Bioanal Chem; 2009 Jan; 393(2):689-97. PubMed ID: 19009285
[TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.
Fukai Y; Hirata M; Ueno M; Ichikawa N; Kobayashi H; Saitoh H; Sakurai T; Kinoshita K; Kaise T; Ohta S
Biol Pharm Bull; 2006 May; 29(5):1022-7. PubMed ID: 16651738
[TBL] [Abstract][Full Text] [Related]
29. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
30. Speciation of arsenic in biological samples.
Mandal BK; Ogra Y; Anzai K; Suzuki KT
Toxicol Appl Pharmacol; 2004 Aug; 198(3):307-18. PubMed ID: 15276410
[TBL] [Abstract][Full Text] [Related]
31. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
[TBL] [Abstract][Full Text] [Related]
32. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
Lin CJ; Wu MH; Hsueh YM; Sun SS; Cheng AL
Cancer Chemother Pharmacol; 2005 Feb; 55(2):170-8. PubMed ID: 15322825
[TBL] [Abstract][Full Text] [Related]
33. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia.
Kiguchi T; Yoshino Y; Yuan B; Yoshizawa S; Kitahara T; Akahane D; Gotoh M; Kaise T; Toyoda H; Ohyashiki K
Leuk Res; 2010 Mar; 34(3):403-5. PubMed ID: 19733394
[TBL] [Abstract][Full Text] [Related]
34. Arsenic speciation in the blood of arsenite-treated F344 rats.
Chen B; Lu X; Shen S; Arnold LL; Cohen SM; Le XC
Chem Res Toxicol; 2013 Jun; 26(6):952-62. PubMed ID: 23734817
[TBL] [Abstract][Full Text] [Related]
35. Arsenic methylation metabolism and liver injury of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Wang H; Xi S; Liu Z; Yang Y; Zheng Q; Wang F; Xu Y; Wang Y; Zheng Y; Sun G
Environ Toxicol; 2013 May; 28(5):267-75. PubMed ID: 23589229
[TBL] [Abstract][Full Text] [Related]
36. Children exposure to inorganic and organic arsenic metabolites: A cohort study in Northeast Italy.
Bocca B; Pino A; Brumatti LV; Rosolen V; Ronfani L; D'Aversa J; Ruggieri F; Petrucci F; Calamandrei G; Barbone F; Alimonti A
Environ Pollut; 2020 Oct; 265(Pt B):114826. PubMed ID: 32454361
[TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia.
Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ
Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395
[TBL] [Abstract][Full Text] [Related]
38. A biological indicator of inorganic arsenic exposure using the sum of urinary inorganic arsenic and monomethylarsonic acid concentrations.
Hata A; Kurosawa H; Endo Y; Yamanaka K; Fujitani N; Endo G
J Occup Health; 2016 May; 58(2):196-200. PubMed ID: 27010090
[TBL] [Abstract][Full Text] [Related]
39. Comparison of induction therapy in non-high risk acute promyelocytic leukemia with arsenic trioxide or in combination with ATRA.
Ghavamzadeh A; Jalili M; Rostami S; Yaghmaie M; Aliabadi LS; Mousavi SA; Vaezi M; Fumani HK; Jahani M; Alimoghaddam K
Leuk Res; 2018 Mar; 66():85-88. PubMed ID: 29407588
[TBL] [Abstract][Full Text] [Related]
40. Analysis of gamma-glutamyltransferase in acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
Sui M; Wei H; Zhang Q; Xiu R; Shen X; Zhang Z; Zhou J
Hematology; 2021 Dec; 26(1):58-64. PubMed ID: 33402059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
